Merkel cell carcinoma, or MCC, is so rare that newly diagnosed patients are often the first case their oncologist has ever treated. For many patients, understanding this aggressive skin cancer’s prognosis and treatment begins online, quickly leading to merkelcell.org — and the visionary team behind it.
Over the past two decades, Paul Nghiem, MD, PhD, and the Nghiem Lab have championed innovations in MCC treatment, delivering new treatment options, setting ever-higher standards of care and improving outcomes for MCC patients worldwide. And behind each breakthrough? A dedicated — and growing — community of supporters whose generosity fuels this progress.
